08:50 AM EDT, 04/16/2024 (MT Newswires) -- Compass Therapeutics ( CMPX ) said Tuesday it dosed its first patient in its phase 1 trial of CTX-8371, a potential cancer treatment.

CTX-8371 is a bispecific checkpoint inhibitor. The study includes five ascending doses of CTX-8371 for patients with melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin Lymphoma, and triple negative breast cancer who have progressed on at least one prior regimen containing a checkpoint blocker, the company said.